Shockwave Medical (SWAV) Tops Q3 EPS by 17c, Revenues Beat

Shockwave Medical (NASDAQ: SWAV) reported Q3 EPS of ($0.38), $0.17 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $19.6 million versus the consensus estimate of $14.69 million.

Recent Highlights

• Recognized revenue of $19.6 million for the third quarter of 2020, representing a 73% increase over the third quarter of 2019
• Submitted PMA application for FDA approval of coronary IVL
• DISRUPT CAD III IDE study results of coronary IVL featured as a late breaking presentation at the TCT Connect conference
• DISRUPT PAD III peripheral trial results featured as a late breaking clinical trial presentation at VIVA20 conference
• Expanded the U.S. Field team to over 100 members

“The successes we achieved this quarter on the clinical, financial and operational fronts speak volumes in terms of confirming the value of our proprietary IVL technology for both coronary and peripheral indications and how it uniquely addresses the challenges our customers face when treating severely calcified arteries throughout the body,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Our team has done a remarkable job of maintaining their focus on patients and physicians as we collectively work to navigate the challenges that 2020 has put in front of us all.”

For earnings history and earnings-related data on Shockwave Medical (SWAV) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024